Altimmune Inc (ALT NASDAQ) stock market data APIs
$4.0305
0.06(1.5%)
as of January 9, 2026
Try our APIs with
free plan!
Altimmune Inc Financial Data Overview
Price chart is built with
Anychart
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Prev. Close
4.0305
Open
4.0929
High
4.2105
Low
4.0103
52 wk Range
2.9-7.73
Market Cap
426 M
Shares Outstanding
104 M
Revenue
20 000
EPS
-0.21
Beta
0.03
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Altimmune Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Altimmune Inc data using free add-ons & libraries
Get Altimmune Inc Fundamental Data
Altimmune Inc Fundamental data includes:
- Net Revenue: 20 000
- EBITDA: -90 343 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Altimmune Inc News
New
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide, a novel, investigational GLP-1/glucagon dual receptor agonist, for the tr...
Why Altimmune Is Rising In Pre-market?
(RTTNews) - Altimmune (ALT) announced the FDA has granted Breakthrough Therapy Designation for pemvidutide, a 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with metabolic dys...
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
2025 was a catalyst year for biotech and drug stocks. While the year began on a cautious note for the sector due to concerns over potential tariffs on pharmaceutical imports, the sector rebounded in t...
Friday 12/26 Insider Buying Report: AGIG, ALT
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
